Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Westminster, California Clinical Trials

A listing of Westminster, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (14) clinical trials

A Study to Evaluate the Pharmacokinetics Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis

The primary objective of this study is to evaluate the safety, pharmacokinetics and tolerability of multiple doses of upadacitinib in pediatric subjects with severe atopic dermatitis.

Phase

2.63 miles

Learn More »

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 study in subjects with moderate to severe Hidradenitis Suppurativa. The study is multicenter and will consist of three subject groups. Subjects will be randomized 1:1:1 to a treatment of 10mg avacopan twice daily, 30 mg avacopan twice daily or placebo twice daily ...

Phase

2.75 miles

Learn More »

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis in Patients With nAMD

This is a phase III multicenter, double-masked, randomized, parallel group study in subjects with wAMD. Approximately 580 subjects will be enrolled and randomized in a 1:1 ratio to receive either Lucentis or the investigational product, Xlucane in the study eye once every 4 weeks for 52 weeks. The study eye ...

Phase

2.75 miles

Learn More »

2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD). Secondary Objectives are to: Evaluate the efficacy of REGN3500 in combination with dupilumab compared with placebo treatment in adult patients with moderate-to-severe AD Assess ...

Phase

4.07 miles

Learn More »

Efficacy Safety and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with moderate-to-severe AD. Secondary objectives are to: Assess the safety and tolerability of subcutaneous (SC) doses of REGN3500 ...

Phase

4.07 miles

Learn More »

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance. Participants must take one tablet with water every morning on ...

Phase

4.99 miles

Learn More »

Contact us to find out if you may be a candidate for one of the new investigational medication research studies for Migraine Headaches, at no-cost to you.  

Phase N/A

4.99 miles

Learn More »

The Effects of a Mobile Health Intervention and Health Coach Text Messaging on Cardiovascular Risk of Older Adults

This study, "Fitness Intensive Therapy (Get FIT) to Promote Healthy Living in Older Adults", will test 2 behavioral interventions in community-dwelling older adults (age 60 years) at intermediate and high risk of cardiovascular disease. Get FIT: use of a Fitbit activity tracker, smartphone application to track daily food intake, one ...

Phase N/A

6.12 miles

Learn More »

Irinotecan Hydrochloride Temozolomide and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

PRIMARY OBJECTIVES: I. To determine whether administration of eflornithine (DFMO) in combination with dinutuximab, irinotecan hydrochloride (irinotecan) and temozolomide results in an improved response rate compared to dinutuximab, irinotecan and temozolomide in patients with relapsed or refractory neuroblastoma and therefore is a therapeutic regimen worthy of further testing in patients ...

Phase

6.73 miles

Learn More »

Dose-Escalation and Dose-Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors

This open-label, phase 1b/2 dose-escalation and dose-expansion study is designed to evaluate the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of RMC-4630 in combination with cobimetinib in participants with relapsed/refractory solid tumors.

Phase

6.73 miles

Learn More »